- Home
- ARE vs UTHR Comparison
ARE vs UTHR Comparison
Compare ARE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARE
- UTHR
- Stock Information
- Founded
- ARE 1994
- UTHR 1996
- Country
- ARE United States
- UTHR United States
- Employees
- ARE N/A
- UTHR N/A
- Industry
- ARE Real Estate Investment Trusts
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- ARE Real Estate
- UTHR Health Care
- Exchange
- ARE Nasdaq
- UTHR Nasdaq
- Market Cap
- ARE 13.2B
- UTHR 20.7B
- IPO Year
- ARE 1997
- UTHR 1999
- Fundamental
- Price
- ARE $52.40
- UTHR $470.12
- Analyst Decision
- ARE Hold
- UTHR Buy
- Analyst Count
- ARE 9
- UTHR 12
- Target Price
- ARE $82.43
- UTHR $495.08
- AVG Volume (30 Days)
- ARE 3.3M
- UTHR 568.9K
- Earning Date
- ARE 10-27-2025
- UTHR 10-29-2025
- Dividend Yield
- ARE 10.10%
- UTHR N/A
- EPS Growth
- ARE N/A
- UTHR 16.08
- EPS
- ARE N/A
- UTHR 26.38
- Revenue
- ARE $3,058,395,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- ARE N/A
- UTHR $13.68
- Revenue Next Year
- ARE N/A
- UTHR $5.63
- P/E Ratio
- ARE N/A
- UTHR $17.68
- Revenue Growth
- ARE N/A
- UTHR 13.50
- 52 Week Low
- ARE $51.63
- UTHR $266.98
- 52 Week High
- ARE $112.42
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- ARE 23.30
- UTHR 67.39
- Support Level
- ARE $52.94
- UTHR $444.04
- Resistance Level
- ARE $56.35
- UTHR $464.27
- Average True Range (ATR)
- ARE 2.71
- UTHR 15.76
- MACD
- ARE -0.23
- UTHR 1.66
- Stochastic Oscillator
- ARE 4.41
- UTHR 84.40
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.